Voya Investment Management LLC Has $11.70 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Voya Investment Management LLC grew its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 5.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 74,701 shares of the company’s stock after buying an additional 4,123 shares during the quarter. Voya Investment Management LLC’s holdings in Krystal Biotech were worth $11,703,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. FMR LLC lifted its position in shares of Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company’s stock worth $675,833,000 after buying an additional 21,133 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock worth $450,938,000 after buying an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock worth $411,831,000 after buying an additional 6,600 shares during the last quarter. Hood River Capital Management LLC lifted its position in shares of Krystal Biotech by 2.1% in the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company’s stock worth $80,324,000 after buying an additional 10,622 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Krystal Biotech by 16.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company’s stock worth $79,812,000 after buying an additional 71,200 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Chardan Capital increased their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. HC Wainwright increased their target price on Krystal Biotech from $221.00 to $240.00 and gave the company a “buy” rating in a research note on Monday. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price for the company. Finally, Citigroup increased their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $222.71.

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.

Krystal Biotech Trading Up 1.0 %

KRYS opened at $169.73 on Tuesday. The stock has a market cap of $4.90 billion, a PE ratio of 56.77 and a beta of 0.75. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34. The stock’s 50 day simple moving average is $176.24 and its 200-day simple moving average is $171.50.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Krystal Biotech’s quarterly revenue was up 116.4% compared to the same quarter last year. During the same period last year, the business earned $0.30 earnings per share. Equities analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).